Landscape Capital Management L.L.C. Increases Stock Holdings in Tempus AI, Inc. $TEM

Landscape Capital Management L.L.C. grew its stake in Tempus AI, Inc. (NASDAQ:TEM) by 19.8% during the third quarter, HoldingsChannel reports. The firm owned 136,372 shares of the company’s stock after purchasing an additional 22,581 shares during the quarter. Tempus AI comprises approximately 0.7% of Landscape Capital Management L.L.C.’s portfolio, making the stock its 20th biggest holding. Landscape Capital Management L.L.C.’s holdings in Tempus AI were worth $11,007,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Royal Bank of Canada grew its position in Tempus AI by 201.2% in the 1st quarter. Royal Bank of Canada now owns 25,988 shares of the company’s stock valued at $1,253,000 after buying an additional 17,359 shares during the last quarter. Rhumbline Advisers acquired a new stake in shares of Tempus AI in the 1st quarter worth $116,000. Envestnet Asset Management Inc. boosted its holdings in shares of Tempus AI by 2.6% in the second quarter. Envestnet Asset Management Inc. now owns 62,005 shares of the company’s stock valued at $3,940,000 after acquiring an additional 1,558 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Tempus AI by 281.8% during the second quarter. Bank of New York Mellon Corp now owns 232,741 shares of the company’s stock worth $14,788,000 after acquiring an additional 171,776 shares during the period. Finally, AE Wealth Management LLC acquired a new position in shares of Tempus AI during the second quarter worth about $287,000. 24.22% of the stock is owned by institutional investors and hedge funds.

Tempus AI Price Performance

TEM traded up $1.71 on Friday, hitting $51.24. 1,424,490 shares of the company were exchanged, compared to its average volume of 5,615,373. Tempus AI, Inc. has a fifty-two week low of $36.22 and a fifty-two week high of $104.32. The company has a debt-to-equity ratio of 2.52, a quick ratio of 3.00 and a current ratio of 3.13. The firm has a market capitalization of $9.16 billion, a P/E ratio of -36.16 and a beta of 5.29. The business’s fifty day moving average is $59.45 and its 200 day moving average is $71.91.

Insider Buying and Selling at Tempus AI

In related news, CEO Eric P. Lefkofsky sold 13,587 shares of Tempus AI stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $59.05, for a total transaction of $802,312.35. Following the completion of the transaction, the chief executive officer directly owned 1,989,626 shares of the company’s stock, valued at approximately $117,487,415.30. The trade was a 0.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO James William Rogers sold 10,084 shares of the business’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $59.05, for a total value of $595,460.20. Following the sale, the chief financial officer owned 101,166 shares in the company, valued at approximately $5,973,852.30. The trade was a 9.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 570,143 shares of company stock worth $35,595,055. Corporate insiders own 26.27% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on TEM shares. Weiss Ratings restated a “sell (d-)” rating on shares of Tempus AI in a research report on Thursday, January 22nd. JPMorgan Chase & Co. dropped their target price on Tempus AI from $80.00 to $60.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 25th. Wall Street Zen downgraded Tempus AI from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Stifel Nicolaus set a $60.00 price target on Tempus AI in a report on Wednesday, February 25th. Finally, Canaccord Genuity Group dropped their price objective on Tempus AI from $95.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, December 22nd. Eight investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $78.62.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.